International AIDS Society
International AIDS Society

Industry Liaison Forum

The International AIDS Society-Industry Liaison Forum (IAS-ILF) is a mechanism to inform and support collaboration and partnership between industry and the IAS. Guided by a strong, multi-stakeholder advisory group, it performs this broad task by regularly providing opportunities for industry to understand the IAS’s interests and priorities, and vice versa, seeking common ground to enhance the impact of our response to HIV and related co-morbidities.

What's New

IAS-ILF/CIPHER Thematic Roundtable on Paediatric HIV
Removing barriers and seizing opportunities in paediatric HIV

Following the success of the IAS-ILF Industry Roundtable on Paediatric Antiretrovirals, held in Geneva, Switzerland, in November 2013, the IAS-ILF and the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) teamed up to organize a follow-up roundtable on paediatric HIV. This closed meeting was held in conjunction with AIDS 2014 (20-25 July 2014, Melbourne, Australia). It was aimed at bringing cohorts (through the CIPHER Cohort Collaboration) and industry together for an informal discussion and knowledge sharing between stakeholders, hoping to extend collaboration between cohort investigators and industry. Normative and regulatory agencies were also represented. The IAS-ILF/CIPHER Thematic Roundtable on Paediatric HIV was co-chaired by Lynne Mofenson (US National Institutes of Health, USA) and Shaffiq Essajee (Clinton Health Access Initiative, USA). This thematic roundtable highlighted the common goal shared by stakeholders: contributing to the development and distribution of better antiretroviral regimens to more infants, children and adolescents. Challenges and opportunities were highlighted during the discussion, as well as potential avenues for follow up through the CIPHER Cohort Collaboration.

The meeting agenda, report and presentations are available for download here.

IAS-ILF Corporate Partners


A list of previous sponsoring industry partners is available here.


  Facebook Twitter LinkedIn

30 October 2014
Omega Diagnostics joins the IAS-ILF Corporate Partnership Programme as an IAS-ILF Bronze Partner

10 October 2014
New fixed-dose combination drugs now eligible for 5 years of exclusivity, FDA says

10 October 2014
Harvoni, a hepatitis C drug from Gilead, receives FDA approval

9 October 2014
WHO-WIPO-WTO joint symposium on Innovation and access to medical technologies (5 November 2014, Geneva, Switzerland)

7 October 2014
Bristol-Myers gives up on hepatitis C combination in USA

6 October 2014
Mylan launches generic Combivir (lamivudine/zidovudine) in the US

30 September 2014
Invitation to manufacturers and suppliers of medicinal products for HIV infection and related diseases, including treatment for hepatitis B and C, to submit an Expression of Interest (EOI) for product evaluation to the WHO Prequalification Team

25 September 2014
The Medicines Patent Pool Adds New Sub-Licensing Agreements to Improve Access to Novel ARVs in Developing Countries

23 September 2014
World Health Organization Issues Prequalification of BD FACSPresto Near-Patient CD4 Counter System for HIV/AIDS Monitoring

23 September 2014
Alere to Support Organisation of African First Ladies Against HIV/AIDS (OAFLA) in New Effort to End Mother-to-Child Transmission of HIV and Syphilis

16 September 2014
The IAS-Industry Liaison Forum (IAS-ILF) thanks its outgoing co-chairs: Celia Christie-Samuels (IAS Governing Council) and Sandra Lehrman (Merck); welcomes its two new co-chairs: Kenneth Mayer (IAS Governing Council) and Scott Purdon (ViiV Healthcare)

9 September 2014
NIH Launches Online Database of International Clinical Research Regulations

3 September 2014
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) launches a new round of research grants for 2015

22 August 2014
ViiV Healthcare receives FDA approval for Triumeq

24 July 2014
IAS and ViiV prioritise paediatric HIV research: £1.5 million additional funding from ViiV Healthcare enables the programme expansion

24 July 2014
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF)

Articles from previous years are available here